AusperBio raises $50M to advance AHB-137 for chronic hepatitis B
AusperBio raised $50 million to advance the development of chronic hepatitis B treatment AHB-137. The company said the funding will help it launch Phase…
Margarida Maia, PhD, Science Writer — 
Articles by Margarida Maia
FDA to review linerixibat for PBC-related itching
The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…
Vaccination, testing encouraged as part of Hepatitis Awareness Month
Hepatitis Awareness Month is held every May to raise awareness about viral hepatitis, an inflammation of the liver caused by a virus, and help…
Air pollution may raise intrahepatic cholestasis of pregnancy risk
Exposure to high levels of fine particulate matter, or PM2.5, the most commonly studied air pollutant, and reduced time in the sunlight in the three…
New PFIC3-causing mutations identified in 3 children in China
A study of three children with progressive familial intrahepatic cholestasis type 3 (PFIC3) in China revealed that different disease-causing mutations in the ABCB4 gene,…
Bile acid levels may predict outcome of Kasai surgery for biliary atresia
Measuring the blood levels of bile acids, the main component of the digestive fluid bile, can help predict key clinical outcomes for babies with…
2nd-line PBC treatment options call for personalized care: Analysis
Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…
ABCB4 mutation ID’d as cause of woman’s recurrent cholestasis
A young woman in the U.S. who experienced recurrent cholestasis was later found, with the help of genetic testing, to have a mutation in…
Biliary atresia patient spotlighted in 2025 ALF Liver Life Walk
Domenic Frappolli, who was born with biliary atresia, was named the American Liver Foundation’s (ALF) 2025 National LIVEr Champion. The foundation is spotlighting…
Seladelpar conditionally approved in European Union to help treat PBC
Gilead Sciences’ oral therapy seladelpar has been conditionally approved by the European Commission as a second-line therapy for adults with primary biliary…
